Athersys Inc.

Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. The company currently has five clinical stage programs involving MultiStem, including those for treating inflammatory bowel disease (partnered with Pfizer Inc.), ischemic stroke, damage caused by myocardial infarction and for the prevention of graft-versus-host disease. Athersys has additional pharmaceutical programs in the metabolic and neurological areas, and a broad international network of collaborations with leading clinical and research institutions.

Expert Comments:

Henry McCusker, Regenerative Medicine Investors (3/2/15)
"Athersys Inc. and Chugai Pharmaceutical Co. Ltd. have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. . .Chugai will be responsible for the development and commercialization of MultiStem for ischemic stroke in Japan, and Athersys will have responsibility for product supply."

Jason Kolbert, Maxim Group (3/2/15)
"Athersys Inc. announced a partnership with Japanese pharmaceutical giant Chugai Pharmacetical Co. Ltd. . .a highly experienced leader in Japan and considered to be not only one of the 'Japanese Core' pharmaceutical companies but a pioneer in the introduction of new products. . .especially strong for its hospital-based salesforce. . .Chugai will be responsible for clinical development (trials and cost) and approval in Japan. . .new governmental regulations in Japan have created a fast-track pathway to the marketplace. Japan is all upside for Athersys."

Jason Kolbert, Maxim Group (1/23/15)
"Athersys Inc. is closing in on a major milestone with stroke data from the MultiStem Phase 2 trial coming in Q1/15. . .good data in stroke should be transforming for the company and could drive a valuation inflection for investors. Moving MultiStem to the clinic for acute respiratory distress syndrome with nondilutive funding represents additional upside."

Henry McCusker, Regenerative Medicine Investors (1/22/15)
"Athersys Ltd. has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, to support a Phase 2a clinical study evaluating the administration of MultiStem cell therapy to acute respiratory distress syndrome patients. The grant is expected to provide up to approximately £2M in support over the course of the study. . .the company's stock should benefit as the costs of testing MultiStem will be supplemented."

"Athersys Inc. is studying MultiStem in human trials for stroke, myocardial infarction (MI) and graft-versus-host disease (GvHD). It is in Phase 2 development for stroke and early Phase 1 for MI and GvHD. The firm completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E. Athersys plans to progress its MI program into Phase 2 in Q1/15. The company is looking for a development partner to further its program. Announcing a partnership deal would signal investors that experts have faith in MultiStem, and Athersys' stock price would respond positively." read more >

Christian Glennie, Edison Investment Research (1/12/15)
"Enrolment in the potentially pivotal phase 2 study assessing Athersys Inc.'s MultiStem in ischaemic stroke patients is now complete. With a 90-day primary efficacy endpoint, headline data are expected towards the end of Q1/15. . .across the U.S., EU and Japan, we estimate peak sales of $3B."

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Athersys Inc. Content